SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-124655
Filing Date
2024-11-12
Accepted
2024-11-12 08:30:09
Documents
13
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atos-20241112.htm   iXBRL 8-K 49949
2 EX-99.1 atos-ex99_1.htm EX-99.1 279713
3 GRAPHIC img248274862_0.jpg GRAPHIC 246040
  Complete submission text file 0000950170-24-124655.txt   806400

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atos-20241112.xsd EX-101.SCH 28515
15 EXTRACTED XBRL INSTANCE DOCUMENT atos-20241112_htm.xml XML 4681
Mailing Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125
Business Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

IRS No.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 241443730
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)